These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38315945)

  • 1. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
    Hutchison RM; Fraser K; Yang M; Fox T; Hirschhorn E; Njingti E; Scott D; Bedell BJ; Kistner KM; Cedarbaum JM; Evans KC; Graham D; Martarello L; Mollenhauer B; Lang AE; Dam T; Beaver J
    Neurology; 2024 Mar; 102(5):e209137. PubMed ID: 38315945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Cinpanemab in Early Parkinson's Disease.
    Lang AE; Siderowf AD; Macklin EA; Poewe W; Brooks DJ; Fernandez HH; Rascol O; Giladi N; Stocchi F; Tanner CM; Postuma RB; Simon DK; Tolosa E; Mollenhauer B; Cedarbaum JM; Fraser K; Xiao J; Evans KC; Graham DL; Sapir I; Inra J; Hutchison RM; Yang M; Fox T; Budd Haeberlein S; Dam T;
    N Engl J Med; 2022 Aug; 387(5):408-420. PubMed ID: 35921450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.
    Hutchison RM; Evans KC; Fox T; Yang M; Barakos J; Bedell BJ; Cedarbaum JM; Brys M; Siderowf A; Lang AE
    BMC Neurol; 2021 Nov; 21(1):459. PubMed ID: 34814867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Prasinezumab in Early-Stage Parkinson's Disease.
    Pagano G; Taylor KI; Anzures-Cabrera J; Marchesi M; Simuni T; Marek K; Postuma RB; Pavese N; Stocchi F; Azulay JP; Mollenhauer B; López-Manzanares L; Russell DS; Boyd JT; Nicholas AP; Luquin MR; Hauser RA; Gasser T; Poewe W; Ricci B; Boulay A; Vogt A; Boess FG; Dukart J; D'Urso G; Finch R; Zanigni S; Monnet A; Pross N; Hahn A; Svoboda H; Britschgi M; Lipsmeier F; Volkova-Volkmar E; Lindemann M; Dziadek S; Holiga Š; Rukina D; Kustermann T; Kerchner GA; Fontoura P; Umbricht D; Doody R; Nikolcheva T; Bonni A; ;
    N Engl J Med; 2022 Aug; 387(5):421-432. PubMed ID: 35921451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
    Simuni T; Fiske B; Merchant K; Coffey CS; Klingner E; Caspell-Garcia C; Lafontant DE; Matthews H; Wyse RK; Brundin P; Simon DK; Schwarzschild M; Weiner D; Adams J; Venuto C; Dawson TM; Baker L; Kostrzebski M; Ward T; Rafaloff G;
    JAMA Neurol; 2021 Mar; 78(3):312-320. PubMed ID: 33315105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
    ; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
    JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
    Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
    Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 14. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of Deferiprone in Parkinson's Disease.
    Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
    N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.
    Palma JA; Martinez J; Millar Vernetti P; Ma T; Perez MA; Zhong J; Qian Y; Dutta S; Maina KN; Siddique I; Bitan G; Ades-Aron B; Shepherd TM; Kang UJ; Kaufmann H
    Mov Disord; 2022 Apr; 37(4):778-789. PubMed ID: 35040506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
    ; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
    JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
    Patterson CG; Joslin E; Gil AB; Spigle W; Nemet T; Chahine L; Christiansen CL; Melanson E; Kohrt WM; Mancini M; Josbeno D; Balfany K; Griffith G; Dunlap MK; Lamotte G; Suttman E; Larson D; Branson C; McKee KE; Goelz L; Poon C; Tilley B; Kang UJ; Tansey MG; Luthra N; Tanner CM; Haus JM; Fantuzzi G; McFarland NR; Gonzalez-Latapi P; Foroud T; Motl R; Schwarzschild MA; Simuni T; Marek K; Naito A; Lungu C; Corcos DM;
    Trials; 2022 Oct; 23(1):855. PubMed ID: 36203214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.